Otsuka Holdings Co., Ltd., traded as OSUKF on the OTC Market, is a global healthcare group headquartered in Tokyo, Japan. The company operates through its principal subsidiary, Otsuka Pharmaceutical Co., Ltd., and is primarily engaged in the research, development and commercialization of pharmaceutical products and nutraceuticals. Its product portfolio spans central nervous system therapies, cardiovascular and metabolic treatments, nephrology, and oncology, alongside a range of consumer wellness goods such as nutritional beverages and dietary supplements.
The origins of the Otsuka group date back to 1921 with the founding of its predecessor firm, and in 2008 the current holding company structure was established to streamline governance and strategic direction. Over the decades, Otsuka has introduced several notable pharmaceuticals, including the atypical antipsychotic aripiprazole (marketed in partnership with Bristol-Myers Squibb) and the vasopressin antagonist tolvaptan. Its nutraceutical division produces branded products that address hydration, nutrition and wellness needs in markets across Asia.
Otsuka maintains a presence in more than 25 countries, with research and development sites in Japan, the United States and Europe, and manufacturing facilities in Asia and North America. It serves a diversified customer base ranging from hospitals and specialty pharmacies to retail outlets and direct‐to‐consumer channels. The group’s global footprint enables it to tailor its product offerings to local regulatory requirements and patient demographics.
The company is led by President and CEO Yoshihito Ishizuka, under whose leadership Otsuka has focused on expanding its late‐stage clinical pipeline and strengthening collaborations with academic institutions and biotechnology firms. Going forward, the group aims to advance innovative therapies in areas of unmet medical need while continuing to develop consumer products that support overall health and well‐being.
AI Generated. May Contain Errors.
